In the last trading session, 55184.0 shares of the Turnstone Biologics Corp (NASDAQ:TSBX) were traded, and its beta was 2.15. Most recently the company’s share price was $0.44, and it changed around -$0.02 or -4.75% from the last close, which brings the market valuation of the company to $10.20M. TSBX currently trades at a discount to its 52-week high of $5.75, offering almost -1206.82% off that amount. The share price’s 52-week low was $0.40, which indicates that the current value has risen by an impressive 9.09% since then. We note from Turnstone Biologics Corp’s average daily trading volume that its 10-day average is 0.24 million shares, with the 3-month average coming to 282.30K.

Turnstone Biologics Corp stock received a consensus recommendation rating of Hold, based on a mean score of 2.67. If we narrow it down even further, the data shows that 0 out of 3 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 1 recommended TSBX as a Hold, whereas 0 deemed it a Buy, and 1 rated it as Underweight.

Turnstone Biologics Corp (NASDAQ:TSBX) trade information

Instantly TSBX has showed a red trend with a performance of -4.75% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 0.5100 on recent trading dayincreased the stock’s daily price by 13.73%. The company’s shares are currently down -11.25% year-to-date, but still down -8.16% over the last five days. On the other hand, Turnstone Biologics Corp (NASDAQ:TSBX) is -6.17% down in the 30-day period. We can see from the shorts that 0.44 million shares have been sold at a short interest cover period of 5.42 day(s).

The consensus price target as assigned by Wall Street analysts is $0.5, which translates to bulls needing to increase their stock price by 12.0% from its current value. Analyst projections state that TSBX is forecast to be at a low of $0.5 and a high of $0.5.

Turnstone Biologics Corp (TSBX) estimates and forecasts

Turnstone Biologics Corp share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -81.39 percent over the past six months and at a 29.29% annual growth rate that is well above the industry average of 16.50%.

TSBX Dividends

Turnstone Biologics Corp’s next quarterly earnings report is expected to be released in February.